BIOMAT Database Logo BIOMAT Database Logo

Safety of oral iron chelator L1. 1989

G J Kontoghiorghes, and P Nasseri-Sina, and J G Goddard, and J M Barr, and P Nortey, and L N Sheppard

UI MeSH Term Description Entries
D007502 Iron Chelating Agents Organic chemicals that form two or more coordination links with an iron ion. Once coordination has occurred, the complex formed is called a chelate. The iron-binding porphyrin group of hemoglobin is an example of a metal chelate found in biological systems. Iron Chelates,Agents, Iron Chelating,Chelates, Iron,Chelating Agents, Iron
D008297 Male Males
D011728 Pyridones Pyridine derivatives with one or more keto groups on the ring. Pyridinones
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077543 Deferiprone A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA. 1,2-Dimethyl-3-hydroxy-4-pyridinone,1,2-Dimethyl-3-hydroxypyrid-4-one,1,2-Dimethyl-3-hydroxypyridin-4-one,3-Hydroxy-1,2-dimethyl-4-pyridinone,DMOHPO,Ferriprox,HDMPP,1,2 Dimethyl 3 hydroxy 4 pyridinone,1,2 Dimethyl 3 hydroxypyrid 4 one,1,2 Dimethyl 3 hydroxypyridin 4 one,3 Hydroxy 1,2 dimethyl 4 pyridinone
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013789 Thalassemia A group of hereditary hemolytic anemias in which there is decreased synthesis of one or more hemoglobin polypeptide chains. There are several genetic types with clinical pictures ranging from barely detectable hematologic abnormality to severe and fatal anemia. Thalassemias
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

G J Kontoghiorghes, and P Nasseri-Sina, and J G Goddard, and J M Barr, and P Nortey, and L N Sheppard
Toxicity of oral iron chelator L1.
June 1993, The Journal of the Association of Physicians of India,
G J Kontoghiorghes, and P Nasseri-Sina, and J G Goddard, and J M Barr, and P Nortey, and L N Sheppard
Development of oral iron chelator L1.
April 1993, Lancet (London, England),
G J Kontoghiorghes, and P Nasseri-Sina, and J G Goddard, and J M Barr, and P Nortey, and L N Sheppard
Toxicity of oral iron chelator L1.
April 1993, Lancet (London, England),
G J Kontoghiorghes, and P Nasseri-Sina, and J G Goddard, and J M Barr, and P Nortey, and L N Sheppard
Oral iron chelator L1 and autoimmunity.
April 1993, Blood,
G J Kontoghiorghes, and P Nasseri-Sina, and J G Goddard, and J M Barr, and P Nortey, and L N Sheppard
Future of oral iron chelator deferiprone (L1)
June 1993, Lancet (London, England),
G J Kontoghiorghes, and P Nasseri-Sina, and J G Goddard, and J M Barr, and P Nortey, and L N Sheppard
Future of oral iron chelator deferiprone (L1)
June 1993, Lancet (London, England),
G J Kontoghiorghes, and P Nasseri-Sina, and J G Goddard, and J M Barr, and P Nortey, and L N Sheppard
Clinical trials with oral iron chelator L1.
January 1989, Lancet (London, England),
G J Kontoghiorghes, and P Nasseri-Sina, and J G Goddard, and J M Barr, and P Nortey, and L N Sheppard
Efficacy and safety of oral iron chelator L1 in anaemic rheumatoid arthritis patients.
December 1989, Lancet (London, England),
G J Kontoghiorghes, and P Nasseri-Sina, and J G Goddard, and J M Barr, and P Nortey, and L N Sheppard
Deaths in patients receiving oral iron chelator L1.
October 1993, British journal of haematology,
G J Kontoghiorghes, and P Nasseri-Sina, and J G Goddard, and J M Barr, and P Nortey, and L N Sheppard
Future of oral iron chelator deferiprone. (L1) ICOC committee.
June 1993, Lancet (London, England),
Copied contents to your clipboard!